Mornet M
Poumon Coeur. 1980 Sep-Oct;36(5):349-52.
The oral form of Doxapram, a respiratory analeptic drug with central action, was tested prospectively and successively, the subject being his own control, in 15 patients with stable obstructive chronic respiratory insufficiency (OCRI), but not infected and with a high PaCO2. The efficiency of the product was judged notable nine times, medium four times; only twice was its action judged inefficient. Retrospectively, it was not possible to define the group OCRI with high PaCO2, responding or not to the oral form of Doxapram. In these conditions, the utility of prescribing this molecule is subjected to the control of gasometric efficiency before and after absorption. The frequent efficiency of the product leads to the consideration of a regular use in some obstructive chronic respiratory insufficiency.
多沙普仑是一种具有中枢作用的呼吸兴奋药，其口服剂型在15例稳定型阻塞性慢性呼吸功能不全（OCRI）患者中进行了前瞻性和连续性测试，患者自身作为对照，这些患者未感染且动脉血二氧化碳分压（PaCO2）较高。该产品的疗效被判定显著的有9次，中等的有4次；其作用仅被判定无效2次。回顾性分析发现，无法明确高PaCO2的OCRI组对多沙普仑口服剂型是否有反应。在这种情况下，开具该药物的效用需在吸收前后进行气体测定效率的控制。该产品的频繁有效性使得考虑在一些阻塞性慢性呼吸功能不全中常规使用。
